Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality.

ABSTRACT:

Background and aims

High levels of lipoprotein(a) could worsen the outcome of COVID-19 due to prothrombotic and proinflammatory properties of lipoprotein(a). We tested the hypotheses that during COVID-19 hospitalization i) increased thrombotic activity and inflammation are associated with lipoprotein(a) levels, and ii) lipoprotein(a) levels are associated with rate of hospital death and discharge.

Methods

We studied 211 patients admitted to Copenhagen University Hospital in 2020 with COVID-19, that is, prior to any vaccination. Thrombotic activity was marked by elevated D-dimer while inflammation was marked by elevated interleukin-6, C-reactive protein, and procalcitonin. Patients were followed until death (N = 36) or discharge (N = 175).

Results

A 2-fold higher D-dim

SUBMITTER: Kaltoft M 

PROVIDER: S-EPMC9343714 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature